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ABSTRACT 
The macrolide antibiotic azithromycin improves lung function and prognosis 
among patients with cystic fibrosis or diffuse panbronchiolitis, independent of 
bacterial eradication. Anti-inflammatory effects have been implicated, but data from 
in vivo studies are scarce and the link between abnormal electrolyte content in airway 
surface liquid and bronchial infections remains uncertain.  
In the present study we treated human airway epithelia on filter supports with 
azithromycin and monitored transepithelial electrical resistance. We found that 
azithromycin increased transepithelial electrical resistance of airway epithelia in a 
dose dependent manner. Immunocytochemistry and western blot analysis showed that 
addition of azithromycin changed protein location in cell cultures and induced 
processing of tight juction proteins; claudin-1 and –4, occludin and junctional 
adhesion molecule-A.  These effects were reversible and no effect was seen when 
cells were treated with penicillin or erythromycin. The data indicate that azithromycin 
increases transepithelial electrical resistance of human airway epithelia by changing 
the processing of tight junction proteins. The results are novel and may help explain 
the beneficial effects of azithromycin in patients with cystic fibrosis, diffuse 
panbronchiolitis and community acquired pneumonia. 
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INTRODUCTION 
Respiratory infections remain an important cause of morbidity and mortality 
despite the development of novel antimicrobial agents. New infectious agents emerge 
and multi-resistant bacteria are a growing problem leading to increased interest in host 
defense research that could provide tools in the fight against pulmonary infections. 
Epidemiological studies have generated interesting results regarding lung defense 
mechanisms. An example is the effect of macrolides, a class of commonly prescribed 
antibiotics, on patients with respiratory infections. Treatment with macrolide 
antibiotics improved 5- and 10 year survival among patients with diffuse 
panbronchiolitis (10, 20). This observation set the stage for large studies evaluating 
the effect of macrolide antibiotics on patients with cystic fibrosis (CF). Three recent 
randomized, placebo-controlled trials indicate that azithromycin significantly 
improves lung function by increasing forced expiratory volume in one second (5, 18, 
28). Interestingly, improvement in lung function did not correlate with reduction of 
Pseudomonas aeruginosa or Staphylococcus aureus in sputum, suggesting that the 
favorable effect of azithromycin did not require bacterial eradication (5, 18, 28). Other 
studies found that the combination of a macrolide and a cephalosporin antibiotic 
improved the prognosis of patients with pneumococcal pneumonia compared to 
single-antibiotic treatment (12, 26). Cephalosporins are active against Streptococcus 
pneumoniae but the beneficial effect of additional macrolide therapy on patients with 
this common type of pneumonia is largely unexplained. Speculations regarding the 
mechanism by which azithromycin improves clinical outcome in diffuse 
panbronchiolitis, CF and pneumonia include an antiinflammatory effect, effect on 
sputum rheology, biofilm formation, bacterial adherence and flagellin expression (16, 
17, 24) Several studies have demonstrated the importance of the bronchial epithelium 
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in lung defense (13, 23). In addition to being a mechanical barrier it regulates 
electrolyte content of the airway surface liquid (ASL) (25). In cystic fibrosis, loss of 
cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel 
activity produces abnormal ASL electrolyte and water content. Data also indicate that 
this may decrease lung defense against infections (23). If the electrolyte and water 
content of the ASL does affect lung defense, regulation of ion transport through 
paracellular pathways could be important in preventing lung infections. Tight 
junctions (TJs) located in the apicolateral membrane of epithelia, form a barrier 
between adjacent cells and regulate the movement of ions and solutes across the 
paracellular space. TJs vary among different epithelia in barrier properties, meeting 
different functional requirements for each tissue type. The TJ complex consists of 
three types of transmembrane proteins; claudins, occludin and junctional adhesion 
molecules (JAMs) as well as zonula occludens (ZO) proteins that serve as adaptors to 
the actin cytoskeleton at the cytoplasmic face of TJs (14). Claudins and occludin are 
tetraspan transmembrane proteins with two extracellular loops and cytoplasmic C- 
and N-termini. There are at least 24 members of the claudin family predicted to range 
in size from 20 to 27 kDa and they show distinct tissue expression patterns. Occludin 
is considerably larger at ~65 kDa and is widely expressed at TJs. JAM-A is a single 
pass transmembrane protein of ~40 kDa and a member of the immunoglobulin 
superfamily. 
The importance of claudins as regulators of paracellular ion transport is 
evident in several human diseases. Simon et al. showed that mutations in the gene 
encoding claudin-16 is the cause of recessive renal hypomagnesemia. Their data 
further suggested that claudins could form a selective paracellular ion channel (22). 
Other studies indicate that claudins-3 and -4 are receptors for Clostridium perfringens 
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enterotoxin (9), a common cause of food poisoning. Mutations in claudin-14 are 
associated with a recessive form of deafness where the ionic environment in the 
cochlear duct is altered (27).  To our knowledge no data are available regarding a role 
for occludin or JAM-A in electrolyte transport. 
In this study we show that azithromycin increases transepithelial electrical 
resistance (TER) in human airway epithelia in vitro and affects both localization and 
processing of the tight junction proteins claudin-1, -4, occludin and JAM-A. These 
effects of azithromycin on TJ proteins were specific and reversible but no effects were 
found on the adherens junction protein E-cadherin or after treatment with other 
antibiotics such as penicillin. The results show novel biological effects of a commonly 
used antibiotic on key proteins that maintain respiratory epithelial integrity and could 
be the initial step explaining the clinical benefit from azithromycin treatment in CF, 
diffuse panbronchiolitis and community acquired pneumonia. 
 
MATERIALS AND METHODS 
Cell culture 
Primary bronchial epithelial cells (a gift from prof. Michael J. Welsh, University of 
Iowa, Iowa City, IA) were cultured on plastic flasks coated with Vitrogen 100 
(Cohesion, Palo Alto, CA) in serum- and antibiotic-free bronchial epithelial growth 
medium with supplements (CC3170, Cambrex, East Rutherford, NJ). We  
established an immortalized cell line, VA-10. Transduction of normal human 
bronchial epithelial cells was performed with sterile filtered supernatant from the 
PA317 LXSN packaging cell lines, containing retroviral construct with human 
papilloma virus 16 E6 and E7 (CRL-2203, American Type Culture Collection, 
Rockville, MD), and the neomycin resistance gene. Transduction was done in the 
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presence of 8 µg/ml polybrene (Sigma-Aldrich). Transfected cells were selected by 
cultivation in the presence of 500 µg/ml neomycin (Life Technologies, Gaithersburg, 
MD).  For immunocytochemistry, cells were grown on Chamber Slides (Nalge Nunc, 
Naperville, IL). For TER experiments, cells were grown on Transwell permeable 
support filters (3460, Corning Costar Corporation, Acton MA) and cultured for the 
first day in 50:50 DMEM-Ham´s F-12 medium (Gibco, Burlington, Canada) in 5% 
fetal bovine serum (Gibco). On the day after seeding, the cells were cultured and 
maintained in 50:50 DMEM-Ham´s F-12 medium supplemented with 2% Ultroser G 
(Biosepra, Cergy-Saint-Christophe, France). 
 
Antibiotics 
Azithromycin (Zitromax; Pfizer ApS, Ballerup, Denmark), erythromycin lactobionate 
(Abboticin; Abbot, Solna, Sweden) and penicillin G (Penicillin Leo; Leo, Ballerup, 
Denmark) were dissolved as instructed by the manufacturer and then further diluted to 
the desired concentrations.  
 
Measurement of transepithelial electrical resistance (TER) 
A Millicell-ERS voltohmmeter (Millipore, Billerica, MA) was used to measure the 
TER value of confluent filters. All measurements were done in triplicate and TER 
values were normalized for the area of the filter and were obtained after background 
subtraction.  
 
Growth curve 
Analysis of cell growth was performed using a standard protocol. Cells were plated 
onto 24 well plates and cultured at 37°C in a humidified 5% CO2 atmosphere with or 
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without 40 µg/ml azithromycin. After 24 h, three wells of both cultures were 
trypsinized and counted by using a hemocytometer. This was repeated daily for seven 
days and the results plotted as a growth curve. 
 
Immunocytochemistry 
Immunofluorescent stainings were performed on methanol fixed cells. Primary 
antibodies were as follows: Rabbit anti-JAM-A and -claudin-1, mouse anti-claudin-4, 
-occludin and -E-cadherin antibodies were purchased from Zymed Laboratories (San 
Francisco, CA). We used iso-type specific Alexa Fluor secondary antibody 
conjugates from Molecular Probes (Eugene, OR). Images were captured by Zeiss 
LSM 5 Pascal Confocal Microscope (Carl Zeiss AG, Munich, Germany). 
 
Western blot 
Equal amounts of proteins, as determined by Bradford method (2), were loaded and 
run on a NuPAGE 10% Bis-Tris gel (Invitrogen, Carlsbad, CA) and transferred to a 
polyvinylidene difluoride membrane (Invitrogen). The blots were blocked in 5% non-
fat milk and subsequently incubated with the primary antibody overnight followed by 
an incubation with secondary antibodies, horseradish peroxidase-conjugated anti-
mouse or rabbit for 1 h (Amersham Biosciences UK Ltd., Little Chalfont, England). 
Protein bands were visualized using enhanced chemiluminesecence system and 
Hyperfilm (Amersham Biosciences).  
 
Statistical analysis 
Statistical analaysis was performed using Student´s T-test. Data are mean ± SEM. P 
values <0.05 were considered statistically significant. 
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RESULTS AND DISCUSSION 
Azithromycin increases transepithelial electrical resistance in human airway 
epithelia in vitro. 
We measured TER across airway epithelia after treatment with azithromycin. We 
used 0.4, 4 and 40 µg/ml of azithromycin based on clinical studies showing that in 
patients receiving 250 mg azithromycin daily for four weeks, the median sputum 
concentration of azithromycin was 9,5 µg/ml (range 0.6 – 79.3 µg/ml) (1). We found 
that addition of 40 µg/ml azithromycin to the basolateral side of the epithelium 
increased TER from 1234±29 (control) to 2920±195 Ω cm2 ± SEM (P<0.05, n=24) 
(Fig. 1A). Addition of azithromycin to the apical side had no effect on TER (data not 
shown).  Fig. 1B shows that a single dose of 40 µg/ml azithromycin daily over 4 days 
increased TER by approximately 80%. Erythromycin (30 µg/ml) or penicillin (20 
µg/ml) had no effect on TER (data not shown). To explore the possibility that 
azithromycin produced multiple layers of epithelial cells, we generated a growth 
curve and found that azithromycin treatment resulted in fewer cells (Fig. 1C) 
suggesting that proliferation of epithelial cells does not explain the observed increase 
in TER. Azithromycin did not affect viability and no effect on apoptosis was observed 
as measured by immunostaining and western blot for cleaved caspase-3 (data not 
shown). 
 
Azithromycin changes the processing of claudin-1 and -4. 
Tight junction proteins are required for epithelial integrity, a key component 
of structural and functional lung defense (15). We used specific antibodies to 
determine the cellular location of claudin-1 and -4. Epithelia were cultured on glass 
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slides and treated with azithromycin continuously from seeding, or after reaching 
confluence.  Under both conditions, immunocytochemistry suggested that 
azithromycin shifted claudin-1 and -4 to an intracellular location (Fig. 2A). To further 
characterize this effect we used western blot analysis. Lysates from cells produced a 
band consistent with the molecular weight of claudins (~23 kDa). Interestingly, a 
rapidly migrating band (~10 kDa) in addition to the expected 23 kDa band (Fig. 2B) 
was produced after treatment with azithromycin (20 and 40 µg/ml). The smaller sized 
band was detected both with claudins-1 and -4. These data indicate that azithromycin 
affects the processing of claudin-1 and -4. Azithromycin produced the same 
processing pattern for claudin-1 in two other cell lines, the alveolar epithelial A549 
and the breast luminal epithelial D382 (data not shown) suggesting that this effect is 
general in epithelial cells. The processing of TJ proteins could affect lung defense 
mechanisms such as the mechanical barrier function or the regulation of airway 
surface liquid electrolytes. Interestingly, earlier studies suggest that azithromycin 
improves outcome in patients with CF, diffuse panbronchiolitis and pneumonia, 
independent of antibacterial effects. The data presented here might help explain some 
of the beneficial clinical effects of azithromycin. Unlike azithomycin, penicillin or 
erythromycin did not affect the processing of claudin-1 (Fig. 2C).   
One potential mechanism by which azithomycin might alter the processing of 
tight junction proteins is activation of proteolytic enzymes. The size of the rapidly 
migrating band in the claudin experiments could be consistent with a cleavage site in 
the cytoplasmic loop. This could affect the structure or location of the extracellular 
loops of claudins that have been shown to determine charge selectivity and TER (3, 
4). However, several other possibilities exist and the origin of the rapidly migrating 
band requires further analysis by immunoprecipitation and amino acid sequencing. 
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Azithromycin changes the processing of occludin and JAM-A. 
To test the possibility that azithromycin affected the processing of occludin, 
JAM-A or E-cadherin, we used immunocytochemistry and western blot analysis. 
Figure 3A indicates that azithromycin induces intracellular location of occludin and 
JAM-A but does not affect the location of E-cadherin. Analysis of occludin protein 
expression revealed a ~65 kDa band consistent with the molecular weight of full 
length occludin (Fig. 3B). Interestingly, a shift towards a smaller sized band ~40 kDa 
was observed in lysates from cells treated with azithromycin. Azithromycin also 
affected the expression of JAM-A, producing two rapidly migrating bands in addition 
to the expected 36-41 kDa band. In contrast, the western blot of E-cadherin was 
unaffected by azithromycin (Fig. 3B). 
The intracellular accumulation of occludin, claudins and JAM-A after 
treatment with azithromycin is a puzzling phenomenon. Protein retention in 
endoplasmic reticulum or in Golgi apparatus, allowing cleavage, is a potential 
explanation for the effect of azithromycin on the processing of TJ proteins (Fig. 2A 
and 3A). Recent studies by Howe et al. demonstrate that cells treated with TGFβ 
resulted in perinuclear accumulation of the CFTR chloride channel in epithelial cells. 
This was shown to be dependent on reorganization of the actin cytoskeleton. Exposure 
to TGFβ caused reorganization of F-actin into elongated stress fibers, in marked 
contrast to the more diffuse F-actin in control epithelial cells (8). Since the TJ 
complex is linked to the actin cytoskeleton through ZO proteins, future studies should 
address this issue. 
The expression of nonjunctional cell adhesion molecules may be affected by 
azithromycin. Semaan et al. found no significant effect of azithromycin on plasma 
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levels of sICAM in patients with coronary artery disease (21). In contrast, Hillis et al. 
showed that a 5-day azithromycin course in patients recovering from an acute 
coronary syndrome reduced serum levels of sICAM-1 (7). By studying the effect of 
azithromycin on nonjunctional cell adhesion molecules we could have made our 
observations more specific. However, our data showing that azithromycin does not 
affect the processing of E-cadherin suggest that its effect on claudin-1, -4, occludin 
and JAM-A is specific. In addition, our model focuses on transepithelial electrolyte 
transport and tight junction proteins. 
Interestingly, erythromycin neither affected TER nor the processing of TJ 
proteins. This suggests that unlike the antiinflammatory effects of macrolides, the 
effects on TER and the processing of TJ proteins found in our study are specific to 
azithromycin. Azithromycin is derived from erythromycin, the chemical difference is 
a methyl-substituted nitrogen atom incorporated into the lactone ring. Wheather this is 
required in the macrolide chemical structure to affect the processing of TJ proteins 
should be further investigated. The successful management of DPB with erythromycin 
has been explained by its antibacterial and antiinflammatory effects. The etiology of 
DPB remains unknown. Unlike CF, DPB has not been shown to be caused by defects 
in transepithelial electrolyte transport. Therefore, the clinical effect of azithromycin in 
CF patients could be caused by its common macrolide effects in addition to its 
specific effects on transepithelial electrolyte transport.  
 
The effect of azithromycin on the processing of claudin-1 and occludin is 
reversible. 
To test if the effect of azithromycin on the processing of claudin-1 and 
occludin was reversible we applied azithromycin to epithelia daily for four days and 
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maintained the culture without azithromycin. Protein was extracted before treatment 
and then daily. The data show that the effect of azithromycin on claudin-1 and 
occludin is evident 24 h after first exposure to azithromycin. The effect is reversed at 
day 5, 24 h after removal of azithromycin (Fig. 4).  
 
Conclusion 
 The study shows that azithromycin increases TER and affects the processing 
of tight junction proteins in human airway epithelia in vitro. The data do not define an 
association between altered protein processing and TER modification. However, such 
association is suggested by various earlier studies;  the extracellular loops of claudins 
contain charged amino acids (19), the expression of different claudins increases or 
decreases TER (6) and, claudins create charge-selective channels in certain epithelial 
paracellular pathways (4).  
The effects of azithromycin reported here are novel and may have implications 
for lung defense. Lee et al. (11) found that confluent low-TER airway epithelia bound 
25 times more P. aeruginosa than confluent high-TER airway epithelia and the 
bacterium bound frequently at cell borders, indicating that tight junctions might be 
involved. Claudins or other tight junction proteins are potential therapeutic targets in 
CF and other diseases of abnormal transepithelial ion transport. Future studies might 
attempt to better define the effect of azithromycin and other antibiotics on the function 
of tight junction proteins. Such work could be important in light of recent 
international pneumonia epidemics and increasing bacterial resistance to multiple 
antibiotics.  
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FIGURE LEGENDS 
Figure 1. 
A. Effect of azithromycin on TER of human airway epithelia in vitro. Human 
airway epithelial cells were cultured on Transwell filters. After reaching confluence 
azithromycin (0.4, 4.0 and 40 µg/ml) was added to the basolateral side of epithelia 
every 48 h for 8 days. TER was measured using a Millicell-Electrical Resistance 
System. Data are mean ± SEM, n=3. Azithromycin increased TER in a dose-
dependent manner.  
B. Azithromycin increases TER in human airway epithelia.  
Measurements were made at day 0 (open bars), before any treatment, and at day 4 
(solid bars), after four doses of 40 µg/ml azithromycin. Data are  mean ± SEM, n=6.  
Azithromycin 40 µg/ml daily increased TER significantly (P<0.0001). 
C. Growth curve.  
Human airway epithelial cells were cultured on 24-well plates and treated 
continuously with 40 µg/ml azithromycin. Data are mean ± SEM, n=3. Azithromycin 
40 µg/ml decreases cell proliferation. 
 
Figure 2.  
A. Immunocytochemical analysis of the effect of azithromycin on the expression 
of claudin-1, and –4. Human airway epithelial cells were cultured on chamber slides. 
Green indicates expression of claudin-1 or -4. Left row; control. Right row; after 
treatment with 40 µg/ml azithromycin. 
B. Western blot analysis of the effect of azithromycin on the expression of 
claudin-1, and –4. Equal amounts of protein from cells treated with different 
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concentrations of azithromycin were subjected to western blot analysis. Blotting for 
claudin-1 and –4 revealed a rapidly migrating band in lysates from cells treated with 
40 µg/ml azihromycin. 
C. Effect of penicillin and erythromycin on the expression of claudin-1. Equal 
amounts of protein from human airway epithelial cells treated with penicillin or 
erythromycin were subjected to western blot analysis. Unlike azithromycin, a rapidly 
migrating band was not observed. 
 
Figure 3.  
Effect of azithromycin on the expression of occludin, JAM-A and E-cadherin. 
A. Immunocytochemistry. Human airway epithelial cells were cultured on chamber 
slides. Green indicates expression of junctional molecules. Left row; control. Right 
row; after treatment with 40 µg/ml azithromycin. 
B. Equal amounts of protein from cells treated with different concentrations of 
azithromycin were subjected to western blot analysis. Blotting for occludin and JAM-
A revealed a rapidly migrating band in lysates from cells treated with 40 µg/ml 
azithromycin. 
 
Figure 4. 
Reversible effect of azithromycin on claudin-1 and occludin. 
Confluent cells were treated with 40 µg/ml azithromycin daily for 4 days. After day 4 
cells were cultured with medium alone. Equal amounts of protein were subjected to 
western blot analysis. Protein was extracted before addition of azithromycin and then 
daily for seven days and again on day 9. 
